Special Issue

Novel Advance in COVID-19 and Neuroscience

Message from the Guest Editor

Towards the end of 2019, a new respiratory syndrome, now known as coronavirus disease 2019 (COVID-19), was reported in Wuhan, China. Since then, the SARS-CoV-2 infection has spread globally. Now, after two years of the pandemic, there is robust evidence documenting that COVID-19 extends beyond the pulmonary system. Among all the organs involved, the brain is one of the most severely affected. A steep surge or worsening of neurologic and psychiatric syndromes has been reported during and after SARS-CoV-2 infection, including confusion, depression, anxiety, post-traumatic stress disorder, dementia, and psychosis. However, despite the efforts made to define, classify, and treat COVID-19-related neuropsychiatric diseases, their characteristic underlying neurobiology remains largely unknown. Therefore, the aim of the present Special Issue, published in the *Journal of Personalized Medicine,* is to provide a comprehensive description of the neurological and psychiatric effects of COVID-19. Advances in diagnosis, definition of pathophysiological models, and treatment strategies will be further investigated.

Guest Editor

Dr. Alessio Simonetti

1. Department of Geriatrics, Neuroscience and Orthopedics, Fondazione Policlinico Universitario A. Gemelli IRCCS, Università Cattolica del Sacro Cuore, Rome, Italy
2. Menninger Department of Psychiatry and Behavioral Sciences, Baylor College of Medicine, Houston, TX, USA

Deadline for manuscript submissions

closed (25 April 2023)

Journal of Personalized Medicine

About the Journal

Message from the Editor-in-Chief

Journal of Personalized Medicine (*JPM*; ISSN 2075-4426) is an international, open access journal aimed at bringing all aspects of personalized medicine to one platform. *JPM* publishes cutting edge, innovative preclinical and translational scientific research and technologies related to personalized medicine (e.g., precision medicine, pharmacogenomics/proteomics, systems biology, 'omics association analysis). *JPM* is covered in Scopus, the Science Citation Index Expanded (SCIE), PubMed, PMC, Embase, and other databases.

Editor-in-Chief

Prof. Dr. Kenneth P.H. Pritzker
Department of Laboratory Medicine and Pathobiology, Department of Surgery, University of Toronto, 6 Queens Pk Crescent W,F, Toronto, ON M5S 3H2, Canada

Author Benefits

High Visibility:
indexed within Scopus, PubMed, PMC, Embase, and other databases.

Journal Rank:
CiteScore - Q1 (Medicine (miscellaneous))

Rapid Publication:
manuscripts are peer-reviewed and a first decision is provided to authors approximately 21.5 days after submission; acceptance to publication is undertaken in 3.5 days (median values for papers published in this journal in the first half of 2025).